NCT06926088Active, not recruiting
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer
Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer: a Multi-center, Real-world Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2025
Brief summary (registry, in English)
Exploring the Impact of body mass index on the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in advanced breast cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 30 Mar 2025
- Start date
- Dec 2016
- Primary completion date
- Dec 2025
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06926088
What you commit to
- Study type: Observational
- Planned participants: 500
- From Dec 2016 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- CDK4/6 inhibitors as neoadjuvant or adjuvant therapy;
Other
- Significantly missing diagnostic and treatment data from patients' medical records;
- Participation in other clinical trials before and during the data collection period.
Who the study is looking for
- 18 years of age and above;
- Women of any menstrual status;
- Histologically confirmed recurrent or metastatic breast cancer, including patients initially diagnosed as stage IV or locally advanced inoperable;
- Patients with histological pathology that is clearly HR-positive/HER2-negative breast cancer, or if there is metastatic pathology, the histological pathology of the metastatic foci shall prevail. (Those with ER intensity \>1% cellular nuclear staining)
- Patients have at least 3 more fully documented medical records at the enrolled centre, including at least 1 inpatient record.
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiangsu Provincial People's Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.